A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs

Update Il y a 4 ans
Reference: NCT00810277

Woman and Man

  • | Country :
  • Finland
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This single arm study will assess the safety and efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to current non-biologic DMARDs. Patients will receive iv infusions of tocilizumab 8mg/kg every 4 weeks for a total of 6 infusions, either as monotherapy or in combination with their current non-biologic DMARDs.


Inclusion criteria

  • Rheumatoid Arthritis

Links